TG Therapeutics, Inc. (NASDAQ:TGTX) Stake Raised by Advisory Services Network LLC

Advisory Services Network LLC grew its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 19.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,359 shares of the biopharmaceutical company’s stock after purchasing an additional 1,693 shares during the period. Advisory Services Network LLC’s holdings in TG Therapeutics were worth $312,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Bleakley Financial Group LLC purchased a new position in shares of TG Therapeutics during the 4th quarter valued at $245,000. Castellan Group acquired a new position in TG Therapeutics in the 4th quarter worth about $8,539,000. Barclays PLC lifted its holdings in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares in the last quarter. Finally, Stratos Wealth Advisors LLC bought a new position in TG Therapeutics during the fourth quarter valued at approximately $241,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $38.32 on Friday. The company has a market cap of $6.02 billion, a price-to-earnings ratio of -383.16 and a beta of 2.14. The business has a 50 day moving average price of $36.20 and a 200 day moving average price of $31.74. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. Research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on TGTX shares. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.